Ratification Date: 20/03/2025
Next Review Date: 20/03/2027
Abacavir + dolutegravir + lamivudine (Triumeq®) for HIV infection in combination with other antiretroviral drugs
| Drug Name (Brand) | Abacavir + dolutegravir + lamivudine (Triumeq®) | |||
| Indication | HIV infection in combination with other antiretroviral drugs | |||
| Traffic Light Classification | Red | |||
| NICE TA (plus
link) |
No associated NICE TA | |||
| Further Information:
NICE recommendations, summary of meeting discussions, links to additional supporting docs etc.
May 2018: This treatment is NHS England commissioning responsibility. NHS England Policy: B06/P/b
Noted by the TAG and recommended to be added to the TAG’s database in line with the Norfolk and Waveney CCGs’ Combined Commissioned Drug Therapies List (March 2018)
|
||||
| Date of TAG recommendation /
ratification |
5/1/2018 | Review Date | 5/1/2020 | |